AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02794103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
Study NCT00854074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ElectroCore RMS-1100 Resolution Motility System™
Description: An electrical neurostimulation signal will be applied to the spine
Study NCT03632187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subcutaneous abatacept every weeks during 3 months
Study NCT03632187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subcutaneous placebo every week during 3 months
Study NCT04059731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition supplement
Description: Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
Study NCT04059731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition supplement
Description: Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
Study NCT02608268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
Study NCT02608268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
Study NCT02608268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: commercially available chemotherapy
Study NCT00745992 — intervention group
Intervention type: OTHER
Intervention: Blood drawn (lab data)
Description: 1. Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~2. Check genetic polymorphism of liver enzyme 3-5 days after start of drug
Study NCT00460031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 400 tid
Study NCT00460031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
Study NCT00460031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: 20mg qam 10mg qhs
Study NCT01030523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
Description: ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
Study NCT01030523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
Description: ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
Study NCT02086864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactose/sucrose granule (Individualized homeopathic medicine treatment)
Description: The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
Study NCT02086864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lactose/sucrose pill
Study NCT02086864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathic consultation
Study NCT02086864 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Homeopathic consultation
Study NCT02407769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Late evening supplementation with branched chain amino acids
Description: The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
Study NCT02407769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Late evening supplementation with branched chain amino acids
Description: The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
Study NCT01697865 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfer group
Study NCT01697865 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Study NCT05717010 — intervention group
Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
Study NCT03927612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality perspective taking training
Description: Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
Study NCT03927612 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Virtual reality control perspective
Description: Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
Study NCT04311879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft tissue Diode laser application
Description: post-operative soft tissue diode laser application
Study NCT04311879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mock diode laser application
Study NCT02807350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overminus treatment
Description: spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
Study NCT02807350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-overminus treatment
Description: spectacles with full cycloplegic refraction without overminus
Study NCT01315756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Few Touch Application (FTA)
Description: The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user.
Study NCT01315756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of FTA and health counseling based on TTM and CBT
Description: The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
Study NCT03862274 — intervention group
Intervention type: OTHER
Intervention: CLN2 Treatment
Description: Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
Study NCT02189239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zeller Entspannung film coated tablet
Study NCT02189239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02189239 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Treatment
Study NCT02027532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT02736487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: True-Washout-Sham Air Filtration Intervention
Description: This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
Study NCT02736487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham-Washout-True Air Filtration Intervention
Description: This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
Study NCT02034786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue collection
Description: Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia.
Study NCT02034786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transdermal injection
Description: Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
Study NCT02034786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal injection
Description: Transdermal injection of hyaluronic acid only.
Study NCT03424265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAA mixture
Description: Dietary supplement intervention for 12-weeks
Study NCT03424265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (whey protein)
Description: Dietary supplement intervention for 12-weeks
Study NCT02804984 — intervention group
Intervention type: GENETIC
Intervention: ICUS
Study NCT02234375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
Study NCT01528072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynesys Spinal System
Description: Dynesys Spinal System will be used for all subjects
Study NCT03567837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructose + Glucose Beverage
Description: The intervention is an oral sugar challenge with blood sampling over three hours.
Study NCT03567837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose + Glucose Beverage
Description: The intervention is an oral sugar challenge with blood sampling over three hours.
Study NCT02106234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No prophylactic iv hydration
Description: Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
Study NCT03078621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Therapy
Description: Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
Study NCT01099436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT01099436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT01099436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Study NCT00942396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Field Digital Mammogram (Planmed Sophie Nuance)
Description: Full Field Digital Mammogram
Study NCT02229318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FruitiVits
Description: Daily administration of FruitiVits dietary supplement
Study NCT00661076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil
Description: 10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
Study NCT00661076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms weekly for 48 weeks
Study NCT00661076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms weekly for 48 weeks
Study NCT02560337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study NCT04674046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Description: Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
Study NCT04674046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative treatment
Description: Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
Study NCT04674046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized education
Description: All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
Study NCT02799758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK-104-CR
Description: NK-104-CR 8 mg for 52 weeks
Study NCT02799758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livalo® IR
Description: Livalo® IR 4 mg daily for 52 weeks
Study NCT02799758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for NK-104-CR)
Description: NK-104-CR 8 mg placebo for 52 weeks
Study NCT02799758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Livalo® IR)
Description: Livalo® IR 4 mg placebo for 52 weeks
Study NCT01957748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SoC + ALERT Intervention
Description: Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
Study NCT02793518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological tests
Study NCT02620579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol LA (60 mg)
Description: Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
Study NCT02620579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol LA (60 mg)
Description: Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
Study NCT00355186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracoronary bone marrow cells infusion
Description: intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described
Study NCT03756298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
Study NCT03756298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
Study NCT03756298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
Study NCT02990208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Description: Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens \& Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
Study NCT02990208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)